BBOT logo

BBOT
BridgeBio Oncology Therapeutics Inc.

120
Mkt Cap
$713.09M
Volume
164,854.00
52W High
$14.87
52W Low
$8.51
PE Ratio
-5.96
BBOT Fundamentals
Price
$8.91
Prev Close
$9.03
Open
$8.80
50D MA
$10.34
Beta
2.52
Avg. Volume
158,570.81
EPS (Annual)
-$4.30
P/B
1.73
Rev/Employee
$0.00
$32.76
Loading...
Loading...
News
all
press releases
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 1.3% - Should You Sell?
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 1.3% - Should You Sell...
MarketBeat·12h ago
News Placeholder
More News
News Placeholder
BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners' Global Healthcare Conference to outline its strategy around next-generation RAS therapeutics, highlighting three...
MarketBeat·22d ago
News Placeholder
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Quarterly Earnings Results
BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, topping analysts' consensus...
MarketBeat·28d ago
News Placeholder
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Gap Up After Better-Than-Expected Earnings
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Gap Up Following Better-Than-Expected Earnings...
MarketBeat·28d ago
News Placeholder
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target Raised to $29.00 at HC Wainwright
HC Wainwright lifted their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a "buy" rating in a report on Friday...
MarketBeat·28d ago
News Placeholder
BridgeBio Oncology Touts Best in RAS Pipeline, Highlights BBO-8520 Response and Combo Tolerability
Executives from BridgeBio Oncology Therapeutics (NASDAQ:BBOT) outlined the company's strategy to build what they call the Best in RAS pipeline during an Oppenheimer-hosted discussion, emphasizing...
MarketBeat·1mo ago
News Placeholder
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Up 11.3% - Still a Buy?
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading 11.3% Higher - What's Next...
MarketBeat·2mo ago
<
...
1
>

Latest BBOT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.